Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dietary Supplement Sector Warnings Jump With FDA 'Program Alignment'

Executive Summary

Some stakeholders complained FDA inspectors unfamiliar with Part 111 inappropriately held supplement firms to drug or food product manufacturing regulations, but the agency's assignment of inspectors with greater expertise on the regulations could be turning up compliance problems in the sector that other ORA officials might have missed.

Advertisement

Related Content

Supplement GMP Inspections Slowing As FDA Makes 'Potential' Data Useful
SARMs Spells Latest 'Synthetic Steroids' FDA Finds In Supplements
Prevagen Study Data Withstand False Ad Complaint By FTC, New York AG
Total Nutrition Latest Own-Label Supplement Marketer Warned On GMP Violations
Supplement Industry Warnings Near 2016 Total Midway Through 2017
FDA 'Program Alignment' Means Inspections Consistency To Supplement Industry

Topics

Advertisement
UsernamePublicRestriction

Register

RS121387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel